Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 24, 2025
Finance
Ascentage lists on NASDAQ as Odyssey, Sionna, Aardvark plot IPOs
In BioCentury’s Finance Report, two more companies plan Hong Kong listings; Disc Medicine, Arctic raise cash
BioCentury | Dec 11, 2023
Product Development
Building on dermatology’s recent success
Targets, mechanisms and indications that stand to benefit from the surging interest in dermatology
BioCentury | Apr 27, 2023
Emerging Company Profile
Evommune: advancing ex-Dermira assets, screening for new programs using human tissue
Backed with $145M since 2020, the biotech has a Phase IIa molecule for atopic dermatitis, plus at least two preclinical programs
BioCentury | Mar 21, 2023
Product Development
March 20 Quick Takes: Latest data add to Karuna’s case in schizophrenia
Plus: two Sangamo partnerships end, Gilead adds Nurix’s degrader
BioCentury | Feb 17, 2023
Discovery & Translation
Engineering bacteria to monitor and treat metabolic disorders; plus on-demand male contraception and more
BioCentury's roundup of translational news
BioCentury | Dec 15, 2022
Finance
Dec. 14 Quick Takes: Alpha-9 lands $75M for radiopharmaceutical pipeline
Plus: Avidity gains 55% on antibody-oligo conjugate data, and updates from Storm, Avidity, Kymera, Icosavax and more
BioCentury | Apr 5, 2022
Politics, Policy & Law
April 4 Quick Takes: University of California continues CRISPR IP fight
Plus Protalix gains on Fabry data and updates from Alnylam, Curis, Gilead, BMS
BioCentury | Oct 28, 2021
Product Development
Kymera adds to the clinical picture for protein degraders
The company digs into the biological effects of its IRAK4 degrader
BioCentury | Jun 29, 2021
Product Development
Surprised by targeted degrader’s single dose potency, Kymera broadens thinking on discovery platform
Company considering shorter term and more infrequent dosing for earlier stage programs
BioCentury | Jun 11, 2021
Product Development
June 11 Quick Takes: First-day bump for Janux; plus Vertex-CRISPR, Curis, Precigen and more
Demand for shares of Janux Therapeutics Inc. (NASDAQ:JANX) was strong enough to lift shares 48% to $25.15 in its first day of trading after the preclinical oncology company priced an upsized number of
Items per page:
1 - 10 of 41